Photoporation: a promising strategy for the generation of CAR-NK cells

Another milestone achieved by Charlotte Hinnekens from Ghent University who was able to generate CAR-NK cells by using photoporation.
Reach out if you wish to know more about the technology used. info@trincebio.com
Gentle Technologies for Cell Processing

We are excited to announce a collaboration by three innovative startups: LiveDrop, Aenitis Technologies, and Trince. The event, titled “Gentle Technologies for Cell Processing”,
Successful VLAIO R&D Grant Application!

Trince received a VLAIO R&D grant to support activities for further developing its novel intracellular delivery technology towards clinical cell-based therapeutic applications. The project runs until April 2025 and has three main objectives:
(1) Successful engineering of human T cells with large effector molecules (plasmids, mRNA and CRISPR/Cas9 RNPs) while preserving T cell fitness and therapeutic efficacy, (2) Develop a prototype device for automated high-throughput transfection of T cells based on Trince’s proprietary photoporation technology and, (3) Successful internal and external evaluation of the automated high-throughput prototype device.
Cell & Gene Therapy Insights – Trince spotlight
Trince is included in the “Emerging technologies & companies in cell & gene therapy manufacturing” review in the Tools of tomorrow issue of Cell & Gene Therapy insights.
White paper with Revatis
Together with Revatis, we successfully used our LumiPore transfection platform to deliver macromolecules into equine and human mesenchymal stem cells.
Clarivate included our co-founders in Highly Cited Researchers list of 2022
We are proud to announce that Clarivate has included both our scientific co-founders in their prestigious list of Highly Cited Researchers for 2022.
82 citations one year after publication
With 82 citations within one year after publication, our Nature Nanotechnology tpaper has received the status of Hot Paper by Web of Science.